Related Experiment Video
Updated: May 1, 2026
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
Prognostic value of miR-96 in patients with acute myeloid leukemia
Jiangning Zhao, Quanyi Lu1, Junfeng Zhu
1Department of Hematology, the First Affiliated Hospital of Sun Yat-Sen University, 510080 Guangzhou, Guangdong, China. quanyilu@hotmail.com.
Objective:
Aberrant expression of miRNA (miR)-96 is associated with tumorigenesis and tumor progression in several solid cancers. However, little is known about the expression and prognostic value of miR-96 in acute myeloid leukemia (AML). Therefore, the aim of this study was to investigate the correlation of miR-96 expression with clinicopathological features and prognosis of AML.
Methods:
Real-time quantitative RT-PCR assay was performed to evaluate the expression levels of miR-96 in mononuclear cells from bone marrow or peripheral blood specimens in 86 patients with newly diagnosed AML.
Results:
Compared with normal controls, miR-96 expression was significantly downregulated in patients with newly diagnosed AML (P < 0.001). In analysis of 14 diagnosis/CR-paired samples, the expression level of miR-96 was found markedly elevated in patients after treatment than before (P < 0.001). Moreover, lower levels of miR-96 were associated with a higher white blood cell count, bone marrow blast count (P < 0.001 and 0.022, respectively), and lower hemoglobin and platelet count (P = 0.036 and 0.033, respectively). Although the low-expression group seemed to have a lower CR rate (53.85% vs 70.0%), there was no significant difference between the two groups (P = 0.213). The low-expression group had a lower relapse-free survival (RFS) (P = 0.038) and overall survival (OS) (P = 0.022) compared with the high-expression group during a median follow-up of 20 months.
Conclusion:
Our data demonstrated that the expression of miR-96 was downregulated in newly diagnosed AML patients and associated with leukemic burden, as well as RFS and OS. This suggests that miR-96 detection might become a potential biomarker of prognosis and monitoring in AML.
Virtual Slides:
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1434808553949498.
Insights
MicroRNA (miR)-96 is downregulated in acute myeloid leukemia (AML) and linked to higher white blood cell counts and poorer survival outcomes. miR-96 may serve as a prognostic biomarker for AML patients.
Area of Science:
- Molecular Biology
- Oncology
- Hematology
Background:
- Aberrant microRNA (miRNA) expression is implicated in various cancers.
- The role of miR-96 in acute myeloid leukemia (AML) pathogenesis and prognosis remains largely unexplored.
Purpose of the Study:
- To investigate the expression levels of miR-96 in AML patients.
- To determine the correlation between miR-96 expression and clinicopathological features.
- To evaluate the prognostic significance of miR-96 in AML.
Main Methods:
- Real-time quantitative RT-PCR was used to measure miR-96 expression in 86 newly diagnosed AML patients.
- Expression levels were compared between AML patients and normal controls.
- Correlation with clinicopathological parameters and survival outcomes (relapse-free survival and overall survival) was analyzed.
Main Results:
- miR-96 expression was significantly downregulated in newly diagnosed AML patients compared to controls.
- Lower miR-96 levels correlated with higher white blood cell and bone marrow blast counts, and lower hemoglobin and platelet counts.
- Patients with lower miR-96 expression exhibited significantly shorter relapse-free survival and overall survival.
Conclusions:
- miR-96 is downregulated in AML and associated with leukemic burden.
- miR-96 expression levels correlate with key clinicopathological features.
- miR-96 holds potential as a prognostic biomarker for monitoring AML patients.
